HDAC9 and acute myeloid leukemia: These findings highlight the potential of combining HDAC inhibitors with AZA/VEN to overcome resistance and enhance therapeutic efficacy, and various clinical trials are assessing their effectiveness, either as frontline AML treatment (NCT05566054 and NCT06386302) or as salvage in R/R and VEN-resistant disease (NCT05305859 and NCT06220162).